@article{3081291,
    title = "Epidermolysis bullosa acquisita: treatment with intravenous
immunoglobulins",
    author = "Gourgiotou, K and Exadaktylou, D and Aroni, K and Rallis, E and and Nicolaidou, E and Paraskevakou, H and Katsambas, AD",
    journal = "Journal of the European Academy of Dermatology and Venereology",
    year = "2002",
    volume = "16",
    number = "1",
    pages = "77-80",
    publisher = "EUROPEAN ACAD DERMATOLOGY & VENEREOLOGY",
    issn = "0926-9959, 1468-3083",
    doi = "10.1046/j.1468-3083.2002.00386.x",
    keywords = "epidermolysis bullosa acquisita; intravenous immunoglobutins",
    abstract = "Epidermolysis bullosa acquisita (EBA) is a rare autoimmune bullous
disorder that is often difficult to treat. Few cases have been reported
and therapy consists mainly of combinations of systemic steroids,
immunosuppressants and, recently, administration of intravenous human
immunoglobulin (IVIg). We describe a case of EBA in which our
therapeutic choices were limited due to the patient’s poor general
condition, including extensive infection of the lesions and a history of
pulmonary tuberculosis. The patient was treated with IVIg at a dose of
400 mg/kg per day for 5 consecutive days every 4 weeks. The treatment
was wen tolerated and the results were satisfactory. It seems that IVIg,
due to its possible immunomodulatory mode of action, can be an
efficacious therapeutic agent in this rare autoimmune disease."
}